Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Conference News TCT 2022

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

Shelley Wood

September 22, 2022

News Conference News ESC 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Michael O'Riordan

August 31, 2022

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Conference News EAS 2022

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

Michael O'Riordan

May 26, 2022

News Conference News EAS 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Michael O'Riordan

May 24, 2022

News Conference News EAS 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Michael O'Riordan

May 24, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2022

Shelley Wood

May 02, 2022

News Conference News ACC 2022

PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI

Todd Neale

April 03, 2022

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

Video

» Interview

ACC 2022: PACMAN AMI - Effects Of Alirocumab On Coronary Atherosclerosis Assessed By Serial Multimodality Intracoronary Imaging In Patients With Acute Myocardial Infarction: A Double-blind, Placebo-controlled, Randomized Trial

April 12, 2022

Advertisement

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

TCTMD’s Top 10 Most Popular Stories for April 2022

PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

ACC 2022: PACMAN AMI - Effects Of Alirocumab On Coronary Atherosclerosis Assessed By Serial Multimodality Intracoronary Imaging In Patients With Acute Myocardial Infarction: A Double-blind, Placebo-controlled, Randomized Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content